{"id":"NCT00806546","sponsor":"NuPathe Inc.","briefTitle":"An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months","officialTitle":"An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2008-12-11","resultsPosted":"2013-03-20","lastUpdate":"2016-02-04"},"enrollment":514,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Disorders"],"interventions":[{"type":"DRUG","name":"NP101","otherNames":[]}],"arms":[{"label":"NP101","type":"EXPERIMENTAL"}],"summary":"This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.","primaryOutcome":{"measure":"Subject Self-examination of Skin Irritation","timeFrame":"24 hours post patch application","effectByArm":[{"arm":"NP101","deltaMin":0.6,"sd":0.86}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":20},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":479},"commonTop":["Application site pain","Application site pruritus","Application site reaction","Application site discoloration","Application site dryness"]}}